Cevimeline

Drugs

Volumn 68, Issue 12, 2008, Pages 1691-1698

  Weber, Juliane ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Profiles; Cevimeline, general; Sjogren's syndrome; Xerostomia

Indexed keywords

CEVIMELINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; PILOCARPINE; PLACEBO; RO ANTIBODY; SNI 2011;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PHARYNGITIS; REVIEW; RHINITIS; SALIVATION; SIDE EFFECT; SINUSITIS; SJOEGREN SYNDROME; SWEATING; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ANIMALS; AREA UNDER CURVE; DIARRHEA; FEMALE; HALF-LIFE; HUMANS; MOLECULAR STRUCTURE; MUSCARINIC AGONISTS; NAUSEA; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS; SJOGREN'S SYNDROME; SWEATING; THIOPHENES; TREATMENT OUTCOME;

EID: 49149090776     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868120-00006     Document Type: Review

References (32)

1. Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjögren's syndrome. Clin Rev Allergy Immunol 2007 Jun; 32 (3): 284-91
2. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. Nat Clin Pract Rheumatol 2006 May; 2 (5): 252-61
3. Fox RI. Sjögren's syndrome. Lancet 2005 Jul 23; 366 (9482): 321-31
4. Al-Hashimi I. Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management. Drugs Aging 2005; 22 (11): 887-99
5. Al-Hashimi I. Sjögren's syndrome: diagnosis and management. Wom Health 2007; 3 (1): 107-22
6. Carsons S. A review and update of Sjögren's syndrome: manifestations, diagnosis, and treatment. Am J Manag Care 2001 Sep; 7 (14 Suppl.): S433-43
7. Ng KP, Isenberg DA. Sjogren's syndrome: diagnosis and therapeutic challenges in the elderly. Drugs Aging 2008; 25 (1): 19-33
8. Suzuki K, Matsumoto M, Nakashima M, et al. Effect of cevimeline on salivary components in patients with Sjögren syndrome. Pharmacology 2005 May; 74 (2): 100-5
9. Masunaga H, Ogawa H, Uematsu Y, et al. Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs. Eur J Pharmacol 1997 Nov 19; 339 (1): 1-9
10. Iwabuchi Y, Masuhara T. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjorgen's syndrome. Gen Pharmacol 1994 Jan; 25 (1): 123-9
11. Iga Y, Arisawa H, Ogane N, et al. (±)-cis-2-methylspiro[1, 3-oxathiolane-5,3′-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol 1998 Nov; 78 (3): 373-80
12. Ohtani Y, Ishii Y, Murasak M, et al. Phase I study of FKS-508: single and multiple dose studies [in Japanese]. Rinsho Iyaku 1990; 6: 1551-76
13. Kashiwazaki S, Okano Y, Miyawaki M. Pharmacokinetics and salivation effect of SNI-2011 in Sjögren's syndrome patients [in Japanese]. Shinryo To Shinyaku 2001 Apr; 38 (4): 393-405
14. Iwabuchi Y, Katagiri M, Masuhara T. Salivary secretion and histopathological effects after single administration of the muscarinic agonist SNI-2011 in MRL/lpr mice. Arch Int Pharmacodyn Ther 1994 Nov-Dec; 328 (3): 315-25
15. Sato N, Ono K, Haga K, et al. Effects of cevimeline on salivation and thirst in conscious rats. Arch Oral Biol 2007 Jan; 52 (1): 26-9
16. Omori Y, Asari T, Maruyama K, et al. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation. Arzneimittelforschung Drug Res 2003; 53 (5): 342-50
17. Arisawa H, Imai E, Fujise N, et al. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system. Arzneimittelforschung Drug Res 2002; 52 (1): 14-20
18. Arisawa H, Fukui K, Fujise N, et al. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle. Arzneimittelforschung Drug Res 2002; 52 (2): 81-8
19. Arisawa H, Fukui K, Masunaga H. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3rd communication: effects on respiratory and cardiovascular systems. Arzneimittelforschung Drug Res 2002; 52 (3): 162-7
20. Arisawa H, Fukui K, Imai E, et al. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: effects on gastrointestinal, urinary and reproductive systems and other effects. Arzneimittelforschung Drug Res 2002; 52 (4): 225-32
21. Daiichi-Sankyo, Inc. Evoxac® capsules (cevimeline hydrochlopeutic ride): US prescribing information [online]. Available from URL: http://www.evoxac.com/prescribing_info.htm [Accessed 2008 Apr 7]
22. Washio T, Kohsaka K, Arisawa H, et al. Pharmacokinetics and metabolism of radiolabelled SNI-2011, a novel muscarinic receptor agonist, in healthy volunteers: comprehensive understanding of absorption, metabolism and excretion using radio-labelled SNI-2011. Arzneimittelforschung Drug Res 2003; 53 (2): 80-6
23. Yasuda H, Niki H. Review of the pharmacological properties and clinical usefulness of muscarinic agonists for xerostomia in patients with Sjogren's syndrome. Clin Drug Invest 2002; 22 (2): 67-73
24. Kashiwazaki S, Ichikawa Y, Touzyou T. Optimal dose of SNI-2011 for xerostomia in Sjögren's syndrome patients [in Japanese]. Shinryo To Shinyaku 2001 Apr; 38 (4): 333-47
25. Yamada H, Nakagawa Y, Wakamatsu E, et al. Efficacy prediction of cevimeline in patients with Sjögren's syndrome. Clin Rheumatol 2007 Aug; 26 (8): 1320-7
26. Ogawa N, Shimoyama K, Karasawa H, et al. Clinical significance of cevimeline hydrochloride in the treatment of dry mouth in patients with Sjögren's syndrome [in Japanese]. Nihon Rinsho Meneki Gakkai Kaishi 2004 Oct; 27 (5): 330-7
27. Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med 2002 Jun 10; 162 (11): 1293-300
28. Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002 Mar; 46 (3): 748-54
29. US FDA. Center for Drug Evaluation and Research application number: 20-989: medical review(s) [online]. Available from URL: http://www.fda.gov/cder/ foi/nda/2000/20-989_Evoxac.htm [Accessed 2008 Apr 12]
30. Ichikawa Y, Kashiwazaki S, Hara M, et al. Double-blind, controlled study of SNI-2011 for xerostomia in Sjögren's syndrome patients: phase III trial [in Japanese]. Shinryo To Shinyaku 2001 Apr; 38 (4): 349-68
31. Leung KCM, McMillan AS, Wong MCM, et al. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin Rheumatol 2008 Apr; 27 (4): 429-36
32. Ichikawa Y, Kashiwazaki S, Hara M, et al. Long-term treatment trial of SNI-2011 for xerostomia in Sjögren's syndrome patients [in Japanese]. Shinryo To Shinyaku 2001 Apr; 38 (4): 369-91